Based on The Plan for Promotion of Medical Research and Development regulated by the government, Japan Agency for Medical Research and Development (AMED) advanced medical research and development centered on 9 integrated projects during AMED’s First Midterm– to Long Term Plan from April 1, 2015 to March 31, 20201). AMED iD3 (Innovative Drug Discovery and Development) Catalyst Unit was granted in September 2017 as a unit of Infrastructure Program for Drug Discovery Seeds Development in Project for Drug Discovery and Development2), which is one of the 9 integrated projects.3)
AMED iD3 Catalyst Unit is operated by Professor and department chief, Masatoshi Hori, Department of Veterinary Pharmacology, Graduate School of Agricultural and Life Sciences of the University of Tokyo, and his staff. The Unit is responsible for public relations activities and plays a role of information dissemination hub of AMED Drug Discovery Booster.
The Unit will disseminate information on achievement of the iD3 Booster Program, Translational Science (TS) and Regulatory Science (RS) aiming at collaboration and promotion of TS and RS which bridge a gap between diversifying medical products and technologies.to develop the products.
|From April 1, 2020, AMED’s Second Midterm- to Long Term Plan was launched. AMED was reorganized and currently 6 integrated projects are advanced.
|The “Project for Drug Discovery and Development” was renamed “Project for Advanced Drug Discovery and Development.”
|The first term (2017.11 - 2022.3) was finished and the second term was started from April 2022.
|Create a new e-Journal
|Peer-reviewed new e-journal will invite original articles on wide-range of topics including outcomes of basic research, cases of translational science which achieved to practical use, and introduction of new drugs, new regulations, and systems. The editorial board will be consist of members from domestic and international academia and the research institutions. Click here for details.
|Held a Symposium
|Translational and Regulatory Sciences Meeting is scheduled in February 2019 as a part of the AMED iD3 Booster projects. Click here for details.
|Operate a Website
|This website aims to be comprehensive website where domestic and international stakeholders from regulatory agencies, medical industries, and academia are able to collect and disseminate information on TS and RS.